| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9136549e91ac59221f028789b57cfb0f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2814
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-78 |
| filingDate |
2012-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_badc2666f24cc474d7950adfce17f9ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea99c971b42cd4237cf6cfe5869b2f50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5da2dbad14734398b7d5fe7a4b7d5f6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d872d012bf2337a88d3d359e40ca0bc |
| publicationDate |
2013-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013083644-A |
| titleOfInvention |
A kit for diagnosing dementia comprising, as an active ingredient, a novel Aβ22 (pE) -42 peptide that specifically binds to amyloid β antibody in blood |
| abstract |
A kit for diagnosing dementia comprising a novel Aβ22 (pE) -42 peptide that specifically binds to amyloid β antibody in blood as an active ingredient. In the present invention, a peptide having a specific sequence that binds to amyloid β antibody is searched, and the Aβ22 (pE) -42 peptide is more immunoreactive with amyloid β antibody in the serum of Alzheimer's disease patients than in normal humans. Therefore, the Aβ22 (pE) -42 peptide can be used as an active ingredient of a dementia diagnosis kit and can be usefully used for diagnosis of dementia that is difficult to diagnose initially. [Selection] Figure 1 |
| priorityDate |
2011-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |